AMENDMENT TO THE CLAIMS

Please cancel Claims 13-21 and 30-33.

1. **(Previously Presented)** A method for identifying an agonist WSX receptor antibody with a strong binding affinity, comprising the steps of

(a) producing one or more agonist antibodies which specifically bind to the extracellular domain of a receptor having a WSX motif comprising the extracellular domain sequence within SEQ ID NO:2, and

(b) selecting an agonist antibody produced in step (a) which binds to said extracellular domain with a Kd of no more than about 1×10^{-7} M

2. **(Previously Presented)** The method of claim 1 wherein said antibody decreases body weight or fat-depot weight or food intake in an *ob/ob* obese mouse.

3. **(Previously Presented)** The method of claim 1 wherein said antibodies produced in step (a) specifically bind to human receptor variant 13.2 (SEQ ID NO:2).

4. **(Previously Presented)** The method of claim 1 wherein said Kd is no more than about 1×10^{-8}M.

5. **(Previously Presented)** The method of claim 4 wherein said Kd is no more than about 1×10^{-9}M.

6. **(Previously Presented)** The method of claim 3 wherein said antibodies also bind to murine receptor having a WSX motif.

7. **(Previously Presented)** The method of claim 1 wherein said antibodies produced in step (a) have an IC50 in a KIRA ELISA of about 0.5 μg/ml or less.

8. **(Previously Presented)** The method of claim 7 wherein said antibodies have an IC50 in a KIRA ELISA of about 0.2 μg/ml or less.

9 - 10 **(Cancelled)**

11. **(Previously Presented)** The method of claim 1 wherein said antibodies bind to the epitope bound by an antibody selected from the group consisting of 2D7 (ATCC Accession Number HB-12249), 1G4 (ATCC Accession Number HB-12243), 1E11 (ATCC Accession Number HB-12248) and 1C11 (ATCC Accession Number HB-12250).

12. **(Currently Amended)** The method of claim 1 wherein said antibodies have complementarity determining region (CDR) residues from an antibody selected from ~~teh~~ the group consisting of 2D7 (ATCC Accession Number HB-12249), 1G4 (ATCC Accession Number HB-12243), 1E11 (ATCC Accession Number HB-12248) and 1C11 (ATCC Accession Number HB-12250).

13. -21. **(Cancelled)**

22. **(Previously Presented)** The method of claim 1 wherein at least one of said antibodies produce in step (a) comprises hypervariable region residues of clone 3 antibody (SEQ ID NO: 48).

23. **(Withdrawn)** The method of claim 1 wherein at least one of said antibodies produced in step (a) comprises hypervariable region residues of clone 4 antibody (SEQ ID NO: 49).

24. **(Withdrawn)** The method of claim 1 wherein at least one of said antibodies produced in step (a) comprises hypervariable region residues of clone 17 antibody (SEQ ID NO: 50).

25. **(Previously Presented)** The method of claim 1 wherein said antibodies produced in step (a) are monoclonal antibodies.

26. **(Previously Presented)** The method of claim 1 wherein at least one of said antibodies produced in step (a) is a human antibody.

27. **(Previously Presented)** The method of claim 1 wherein at least one of said antibodies produced in step (a) is a humanized antibody.

28. **(Previously Presented)** The method of claim 1 wherein at least one of said antibodies produced in step (a) is an antibody fragment.

29. **(Previously Presented)** The method of claim 28 wherein said antibody fragment is an $F(ab')_2$.

30. -33. **(Cancelled)**